Clinical trial NCT00153101: Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
Official title: ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cardiovascular Diseases
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2005-09-12
Enrollment: 31546
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint.

Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.


Eligibility criteria: Inclusion Criteria:

Coronary Artery Disease: Previous Myocardial infarction(\> 2 days prior to informed consent), or stable or previous unstable angina (\> 30 days prior to informed consent) with documented multivessel coronary artery disease or a positive stress test, or multivessel Percutaneous Transluminal Coronary Angioplasty (\> 30 days prior to informed consent), or previous multivessel Coronary Artery Bypass Grafting without angina (if surgery performed \> 4 years prior to informed consent) or with recurrent angina after surgery.

Other High Risk:

1. Peripheral Arterial Disease: Previous limb bypass surgery or angioplasty or amputation, intermittent claudication on history with ankle/arm Blood Pressure ratio \< 0.8 on at least one side, or significant stenosis by angiography or non-invasive testing
2. Previous stroke
3. Transient ischemic Attack \> 7 days and \< 1 year prior to informed consent
4. Diabetes Mellitus (types I or II): with evidence of end-organ damage (retinopathy, Left ventricular hypertrophy, micro or macro albuminuria), or any evidence of previous cardiac or vascular disease.

No definite and specific indication or contraindication for any of the study treatments. Written informed consent.

Exclusion Criteria:

A. Medication use:

1. Inability to discontinue Angiotension Converting Enzyme (ACE) inhibitors or Angiotension 2 receptor antagonists (AIIAs).
2. Patients with known hypersensitivity or intolerance to Angiotension 2 receptor antagonists (AIIAs) or Angiotension Converting Enzyme (ACE)inhibitors.

NOTE: Patients with known intolerance to Angiotension Converting Enzyme inhibitor intolerance ( ACE-I) can be enrolled in the TRANSCEND study.

B. Cardiovascular disease:

1. Symptomatic congestive heart failure.
2. Hemodynamically significant primary valvular or outflow tract obstruction (e.g. aortic or mitral valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic valve).
3. Constrictive pericarditis.
4. Complex congenital heart disease.
5. Syncopal episodes of unknown etiology \< 3 months before informed consent.
6. Planned cardiac surgery or angioplasty within three months.
7. Uncontrolled hypertension on treatment (i.e.Blood pressure ( BP) \> 160/100).
8. Heart transplant recipient.
9. Strokes due to subarachnoid hemorrhage

C. Other conditions:

1. Significant renal disease defined as:

   1. Renal artery stenosis;
   2. Creatinine clearance \< 0.6 ml/min or serum creatinine \> 265 umol/L (\> 3.0 mg/dL);
   3. Hyperkalemia: potassium \> 5.5 mmol/L.
   4. Proteinuria\* (for TRANSCEND only).
2. Hepatic dysfunction as defined by the following laboratory parameters: Serum Glutamate Pyruvate Transaminase( SGPT) Alaninaminotransferase (ALT) or Serum Glutamic Oxaloacetic Transaminase (SGOT) Aspartate aminotransferase (AST) \> than 4 times upper limit of normal or additional criteria for hepatic impairment the upper limit of normal range, total Bilirubin \> 20 umol/L, biliary obstructive disorders.
3. Uncorrected volume depletion or sodium depletion.
4. Primary aldosteronism.
5. Hereditary fructose intolerance.
6. Any other major non-cardiac illness expected to reduce life expectancy or interfere with study participation.
7. Patient is simultaneously taking another experimental drug.
8. Patient with significant disability that precludes regular attendance at clinic for follow-up.
9. Patient has sufficient disability or other incapacity that precludes regular attendance at clinic for follow-up.
10. Unable or unwilling to provide written informed consent.

Primary outcomes:
measure: ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure
timeFrame: 56 months
measure: ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients
timeFrame: 56 months
measure: TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart Failure
timeFrame: 56 months
Secondary outcomes:
measure: ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke
timeFrame: 56 months
measure: ONTARGET. Cardiovascular Death
timeFrame: 56 months
measure: ONTARGET. Non-fatal Myocardial Infarction
timeFrame: 56 months
measure: ONTARGET. Non-fatal Stroke
timeFrame: 56 months
measure: ONTARGET. Hospitalization for Congestive Heart Failure
timeFrame: 56 months
measure: ONTARGET. Doubling of Serum Creatinine in Diabetic Nephropathy Patients
timeFrame: 56 months
measure: ONTARGET. Progression to End Stage Renal Disease (ESRD) in Diabetic Nephropathy Patients
timeFrame: 56 months
measure: ONTARGET. All-cause Mortality in Diabetic Nephropathy Patients
timeFrame: 56 months
measure: ONTARGET. Doubling of Serum Creatinine
timeFrame: 56 months
measure: ONTARGET. Progression to ESRD
timeFrame: 56 months
measure: ONTARGET. New Microalbuminuria
timeFrame: 56 months
measure: ONTARGET. New Macroalbuminuria
timeFrame: 56 months
measure: ONTARGET. Combined Endpoint of Doubling of Serum Creatinine, Progression to ESRD, New Microalbuminuria, or New Macroalbuminuria
timeFrame: 56 months
measure: ONTARGET. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria
timeFrame: 56 months
measure: ONTARGET. Newly Diagnosed Congestive Heart Failure
timeFrame: 56 months
measure: ONTARGET. Cardiovascular Revascularization Procedure
timeFrame: 56 months
measure: ONTARGET. Newly Diagnosed Diabetes
timeFrame: 56 months
measure: ONTARGET. Cognitive Decline
timeFrame: 56 months
measure: ONTARGET. New Onset of Atrial Fibrillation
timeFrame: 56 months
measure: TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction and Non-fatal Stroke
timeFrame: 56 months
measure: TRANSCEND. Cardiovascular Death
timeFrame: 56 months
measure: TRANSCEND. Non-fatal Myocardial Infarction
timeFrame: 56 months
measure: TRANSCEND. Non-fatal Stroke
timeFrame: 56 months
measure: TRANSCEND. Hospitalization for Congestive Heart Failure
timeFrame: 56 months
measure: TRANSCEND. Doubling of Serum Creatinine
timeFrame: 56 months
measure: TRANSCEND. Progression to ESRD
timeFrame: 56 months
measure: TRANSCEND. New Microalbuminuria
timeFrame: 56 months
measure: TRANSCEND. New Macroalbuminuria
timeFrame: 56 months
measure: TRANSCEND. Combined Endpoint of Doubling Serum Creatinine, Progression to ESRD, New Microalbuminuria or New Macroalbuminuria
timeFrame: 56 months
measure: TRANSCEND. Normalisation From Micro- or Macroalbuminuria to Normoalbuminuria
timeFrame: 56 months
measure: TRANSCEND. New Onset of Atrial Fibrillation
timeFrame: 56 months
measure: TRANSCEND. Cognitive Decline
timeFrame: 56 months
measure: TRANSCEND. Newly Diagnosed Diabetes
timeFrame: 56 months
measure: TRANSCEND. Cardiovascular Revascularization Procedure
timeFrame: 56 months
measure: TRANSCEND. Newly Diagnosed Congestive Heart Failure
timeFrame: 56 months
Other outcomes:
Locations:
city: Athens
country: United States
facility: 502.373.0256 Boehringer Ingelheim Investigational Site
state: Alabama
city: Birmingham
country: United States
facility: 502.373.0251 Boehringer Ingelheim Investigational Site
state: Alabama
city: Phoenix
country: United States
facility: 502.373.0182 Boehringer Ingelheim Investigational Site
state: Arizona
city: Phoenix
country: United States
facility: 502.373.0188 Boehringer Ingelheim Investigational Site
state: Arizona
city: Tucson
country: United States
facility: 502.373.0189 Boehringer Ingelheim Investigational Site
state: Arizona
city: Tuscon
country: United States
facility: 502.373.0177 Boehringer Ingelheim Investigational Site
state: Arizona
city: Bentonville
country: United States
facility: 502.373.0209 Boehringer Ingelheim Investigational Site
state: Arkansas
city: Concord
country: United States
facility: 502.373.0173 Boehringer Ingelheim Investigational Site
state: California
city: Harbor City
country: United States
facility: 502.373.0266 Boehringer Ingelheim Investigational Site
state: California
city: Loma Linda
country: United States
facility: 502.373.0283 Boehringer Ingelheim Investigational Site
state: California
city: Los Angeles
country: United States
facility: 502.373.0180 Boehringer Ingelheim Investigational Site
state: California
city: Sacramento
country: United States
facility: 502.373.0175 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 502.373.0165 Boehringer Ingelheim Investigational Site
state: California
city: San Leandro
country: United States
facility: 502.373.0228 Boehringer Ingelheim Investigational Site
state: California
city: Sylmar
country: United States
facility: 502.373.0205 Boehringer Ingelheim Investigational Site
state: California
city: West Hills
country: United States
facility: 502.373.0277 Boehringer Ingelheim Investigational Site
state: California
city: Bridgeport
country: United States
facility: 502.373.0226 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Farmington
country: United States
facility: 502.373.0174 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Washington
country: United States
facility: 502.373.0258 Boehringer Ingelheim Investigational Site
state: District of Columbia
city: Gainesville
country: United States
facility: 502.373.0179 Boehringer Ingelheim Investigational Site
state: Florida
city: Palm Harbor
country: United States
facility: 502.373.0183 Boehringer Ingelheim Investigational Site
state: Florida
city: Panama City
country: United States
facility: 502.373.0240 Boehringer Ingelheim Investigational Site
state: Florida
city: Tampa
country: United States
facility: 502.373.0171 Boehringer Ingelheim Investigational Site
state: Florida
city: Vero Beach
country: United States
facility: 502.373.0282 Boehringer Ingelheim Investigational Site
state: Florida
city: Weston
country: United States
facility: 502.373.0214 Boehringer Ingelheim Investigational Site
state: Florida
city: Augusta
country: United States
facility: 502.373.0161 Boehringer Ingelheim Investigational Site
state: Georgia
city: Augusta
country: United States
facility: 502.373.0193 Boehringer Ingelheim Investigational Site
state: Georgia
city: Augusta
country: United States
facility: 502.373.0201 Boehringer Ingelheim Investigational Site
state: Georgia
city: Conyers
country: United States
facility: 502.373.0223 Boehringer Ingelheim Investigational Site
state: Georgia
city: Sandersville
country: United States
facility: 502.373.0268 Boehringer Ingelheim Investigational Site
state: Georgia
city: Savannah
country: United States
facility: 502.373.0245 Boehringer Ingelheim Investigational Site
state: Georgia
city: Tucker
country: United States
facility: 502.373.0199 Boehringer Ingelheim Investigational Site
state: Georgia
city: Valdosta
country: United States
facility: 502.373.0162 Boehringer Ingelheim Investigational Site
state: Georgia
city: Pocatello
country: United States
facility: 502.373.0203 Boehringer Ingelheim Investigational Site
state: Idaho
city: Burbank
country: United States
facility: 502.373.0244 Boehringer Ingelheim Investigational Site
state: Illinois
city: Chicago
country: United States
facility: 502.373.0272 Boehringer Ingelheim Investigational Site
state: Illinois
city: Olympia Fields
country: United States
facility: 502.373.0217 Boehringer Ingelheim Investigational Site
state: Illinois
city: Des Moines
country: United States
facility: 502.373.0270 Boehringer Ingelheim Investigational Site
state: Iowa
city: Monroe
country: United States
facility: 502.373.0167 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Shreveport
country: United States
facility: 502.373.0158 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Baltimore
country: United States
facility: 502.373.0247 Boehringer Ingelheim Investigational Site
state: Maryland
city: Boston
country: United States
facility: 502.373.0284 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Springfield
country: United States
facility: 502.373.0229 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Wyandotte
country: United States
facility: 502.373.0237 Boehringer Ingelheim Investigational Site
state: Michigan
city: Minneapolis
country: United States
facility: 502.373.0208 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Minneapolis
country: United States
facility: 502.373.0232 Boehringer Ingelheim Investigational Site
state: Minnesota
city: St. Paul
country: United States
facility: 502.373.0231 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Biloxi
country: United States
facility: 502.373.0181 Boehringer Ingelheim Investigational Site
state: Mississippi
city: Cleveland
country: United States
facility: 502.373.0185 Boehringer Ingelheim Investigational Site
state: Mississippi
city: Jackson
country: United States
facility: 502.373.0254 Boehringer Ingelheim Investigational Site
state: Mississippi
city: Kansas City
country: United States
facility: 502.373.0195 Boehringer Ingelheim Investigational Site
state: Missouri
city: St. Louis
country: United States
facility: 502.373.0207 Boehringer Ingelheim Investigational Site
state: Missouri
city: St. Louis
country: United States
facility: 502.373.0239 Boehringer Ingelheim Investigational Site
state: Missouri
city: Omaha
country: United States
facility: 502.373.0279 Boehringer Ingelheim Investigational Site
state: Nebraska
city: North Las Vegas
country: United States
facility: 502.373.0169 Boehringer Ingelheim Investigational Site
state: Nevada
city: Camden
country: United States
facility: 502.373.0157 Boehringer Ingelheim Investigational Site
state: New Jersey
city: East Orange
country: United States
facility: 502.373.0202 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Newark
country: United States
facility: 502.373.0191 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Westwood
country: United States
facility: 502.373.0271 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Bronx
country: United States
facility: 502.373.0150 Boehringer Ingelheim Investigational Site
state: New York
city: Brooklyn
country: United States
facility: 502.373.0213 Boehringer Ingelheim Investigational Site
state: New York
city: Buffalo
country: United States
facility: 502.373.0230 Boehringer Ingelheim Investigational Site
state: New York
city: Kingston
country: United States
facility: 502.373.0288 Boehringer Ingelheim Investigational Site
state: New York
city: New York
country: United States
facility: 502.373.0238 Boehringer Ingelheim Investigational Site
state: New York
city: New York
country: United States
facility: 502.373.0252 Boehringer Ingelheim Investigational Site
state: New York
city: New York
country: United States
facility: 502.373.0286 Boehringer Ingelheim Investigational Site
state: New York
city: Northport
country: United States
facility: 502.373.0166 Boehringer Ingelheim Investigational Site
state: New York
city: Rochester
country: United States
facility: 502.373.0156 Boehringer Ingelheim Investigational Site
state: New York
city: Rochester
country: United States
facility: 502.373.0264 Boehringer Ingelheim Investigational Site
state: New York
city: Scarsdale
country: United States
facility: 502.373.0227 Boehringer Ingelheim Investigational Site
state: New York
city: Westfield
country: United States
facility: 502.373.0163 Boehringer Ingelheim Investigational Site
state: New York
city: Williamsville
country: United States
facility: 502.373.0241 Boehringer Ingelheim Investigational Site
state: New York
city: Durham
country: United States
facility: 502.373.0273 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Winston Salem
country: United States
facility: 502.373.0261 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Fargo
country: United States
facility: 502.373.0222 Boehringer Ingelheim Investigational Site
state: North Dakota
city: Cincinnati
country: United States
facility: 502.373.0155 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cleveland
country: United States
facility: 502.373.0164 Boehringer Ingelheim Investigational Site
state: Ohio
city: Dayton
country: United States
facility: 502.373.0168 Boehringer Ingelheim Investigational Site
state: Ohio
city: Mansfield
country: United States
facility: 502.373.0159 Boehringer Ingelheim Investigational Site
state: Ohio
city: Oklahoma City
country: United States
facility: 502.373.0178 Boehringer Ingelheim Investigational Site
state: Ohio
city: Guthrie
country: United States
facility: 502.373.0259 Boehringer Ingelheim Investigational Site
state: Oklahoma
city: Oklahoma City
country: United States
facility: 502.373.0154 Boehringer Ingelheim Investigational Site
state: Oklahoma
city: Tulsa
country: United States
facility: 502.373.0152 Boehringer Ingelheim Investigational Site
state: Oklahoma
city: Portland
country: United States
facility: 502.373.0243 Boehringer Ingelheim Investigational Site
state: Oregon
city: Erie
country: United States
facility: 502.373.0265 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Philadelphia
country: United States
facility: 502.373.0153 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Sellersville
country: United States
facility: 502.373.0274 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Charleston
country: United States
facility: 502.373.0184 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Columbia
country: United States
facility: 502.373.0248 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Dallas
country: United States
facility: 502.373.0172 Boehringer Ingelheim Investigational Site
state: Texas
city: Dallas
country: United States
facility: 502.373.0187 Boehringer Ingelheim Investigational Site
state: Texas
city: Dallas
country: United States
facility: 502.373.0219 Boehringer Ingelheim Investigational Site
state: Texas
city: Dallas
country: United States
facility: 502.373.0275 Boehringer Ingelheim Investigational Site
state: Texas
city: Fort Worth
country: United States
facility: 502.373.0221 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 502.373.0206 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 502.373.0234 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 502.373.0280 Boehringer Ingelheim Investigational Site
state: Texas
city: Burke
country: United States
facility: 502.373.0249 Boehringer Ingelheim Investigational Site
state: Virginia
city: Seattle
country: United States
facility: 502.373.0281 Boehringer Ingelheim Investigational Site
state: Washington
city: Milwaukee
country: United States
facility: 502.373.0212 Boehringer Ingelheim Investigational Site
state: Wisconsin
city: Capital Federal
country: Argentina
facility: 502.373.350 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 502.373.351 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 502.373.352 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 502.373.353 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 502.373.354 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 502.373.355 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 502.373.356 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 502.373.378 Boehringer Ingelheim Investigational Site
city: Corones Suárez
country: Argentina
facility: 502.373.362 Boehringer Ingelheim Investigational Site
city: Córdoba
country: Argentina
facility: 502.373.357 Boehringer Ingelheim Investigational Site
city: Córdoba
country: Argentina
facility: 502.373.358 Boehringer Ingelheim Investigational Site
city: Córdoba
country: Argentina
facility: 502.373.360 Boehringer Ingelheim Investigational Site
city: Córdoba
country: Argentina
facility: 502.373.361 Boehringer Ingelheim Investigational Site
city: Córdoba
country: Argentina
facility: 502.373.377 Boehringer Ingelheim Investigational Site
city: La Plata
country: Argentina
facility: 502.373.364 Boehringer Ingelheim Investigational Site
city: Mar del Plata
country: Argentina
facility: 502.373.365 Boehringer Ingelheim Investigational Site
city: Mendoza
country: Argentina
facility: 502.373.366 Boehringer Ingelheim Investigational Site
city: Mendoza
country: Argentina
facility: 502.373.376 Boehringer Ingelheim Investigational Site
city: Rosario
country: Argentina
facility: 502.373.367 Boehringer Ingelheim Investigational Site
city: Salta
country: Argentina
facility: 502.373.369 Boehringer Ingelheim Investigational Site
city: Santa Fe
country: Argentina
facility: 502.373.375 Boehringer Ingelheim Investigational Site
city: Tucumán
country: Argentina
facility: 502.373.371 Boehringer Ingelheim Investigational Site
city: Tucumán
country: Argentina
facility: 502.373.373 Boehringer Ingelheim Investigational Site
city: Zárate
country: Argentina
facility: 502.373.374 Boehringer Ingelheim Investigational Site
city: Woden
country: Australia
facility: 502.373.0534 The Canberra Hospital
state: Australian Capital Territory
city: Camperdown
country: Australia
facility: 502.373.0536 Royal Prince Alfred Hospital
state: New South Wales
city: Coffs Harbour
country: Australia
facility: 502.373.0544 Coffs Harbour Cardiovascular Clinic
state: New South Wales
city: Concord
country: Australia
facility: 502.373.0538 Concord Repatriation General Hospital
state: New South Wales
city: Gosford
country: Australia
facility: 502.373.0539 Central Coast Neuroscience Research
state: New South Wales
city: Gosford
country: Australia
facility: 502.373.0556 Gosford Hospital
state: New South Wales
city: Kogarah
country: Australia
facility: 502.373.0542 St. George Hospital
state: New South Wales
city: Kogarah
country: Australia
facility: 502.373.0552 St George Private Hospital
state: New South Wales
city: Kogarah
country: Australia
facility: 502.373.0559 St George Hospital - Dept of Clinical Pharmacology
state: New South Wales
city: Newcastle
country: Australia
facility: 502.373.0528 John Hunter Hospital
state: New South Wales
city: Randwick
country: Australia
facility: 502.373.0535 The Prince of Wales Hospital
state: New South Wales
city: St Leonards
country: Australia
facility: 502.373.0533 Royal North Shore Hospital
state: New South Wales
city: Wollongong
country: Australia
facility: 502.373.0549 Illawarra Regional Hospital
state: New South Wales
city: Chermside
country: Australia
facility: 502.373.0523 The Prince Charles Hospital
state: Queensland
city: Herston
country: Australia
facility: 502.373.0524 Royal Brisbane Hospital
state: Queensland
city: Kippa-Ring
country: Australia
facility: 502.373.0526 Peninsula Clinical Research Centre
state: Queensland
city: Southport
country: Australia
facility: 502.373.0540 Gold Coast Hospital
state: Queensland
city: Woolloongabba
country: Australia
facility: 502.373.0521 Princess Alexandra Hospital
state: Queensland
city: Bedford Park
country: Australia
facility: 502.373.0546 Flinders Medical Centre
state: South Australia
city: Daw Park
country: Australia
facility: 502.373.0550 Repatriation General Hospital
state: South Australia
city: Port Lincoln
country: Australia
facility: 502.373.0551 Port Lincoln "The Investigator" Clinic
state: South Australia
city: Launceston
country: Australia
facility: 502.373.0529 Launceston General Hospital
state: Tasmania
city: Box Hill
country: Australia
facility: 502.373.0531 Box Hill Hospital
state: Victoria
city: Epping
country: Australia
facility: 502.373.0548 The Northern Hospital
state: Victoria
city: Geelong
country: Australia
facility: 502.373.0522 The Geelong Hospital
state: Victoria
city: Parkville
country: Australia
facility: 502.373.0520 Royal Melbourne Hospital
state: Victoria
city: Prahran
country: Australia
facility: 502.373.0525 The Alfred Hospital
state: Victoria
city: Prahran
country: Australia
facility: 502.373.0532 Baker Medical Research Centre
state: Victoria
city: Ringwood East
country: Australia
facility: 502.373.0557 Maroondah Hospital
state: Victoria
city: West Heidelberg
country: Australia
facility: 502.373.0537 Austin & Repatriation Medical Centre
state: Victoria
city: Fremantle
country: Australia
facility: 502.373.0547 Fremantle Hospital
state: Western Australia
city: Nedlands
country: Australia
facility: 502.373.0530 Sir Charles Gairdner Hospital
state: Western Australia
city: Perth
country: Australia
facility: 502.373.0545 Royal Perth Hospital
state: Western Australia
city: Graz
country: Austria
facility: 502.373.1128 Boehringer Ingelheim Investigational Site
city: Wels
country: Austria
facility: 502.373.1125 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 502.373.1126 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 502.373.1127 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 502.373.1129 Boehringer Ingelheim Investigational Site
city: Aalst
country: Belgium
facility: 502.373.1004 Boehringer Ingelheim Investigational Site
city: Anderlecht
country: Belgium
facility: 502.373.1015 Boehringer Ingelheim Investigational Site
city: Antwerpen
country: Belgium
facility: 502.373.1005 Boehringer Ingelheim Investigational Site
city: Bornem
country: Belgium
facility: 502.373.1022 Boehringer Ingelheim Investigational Site
city: Brasschaat
country: Belgium
facility: 502.373.1021 Boehringer Ingelheim Investigational Site
city: Brugge
country: Belgium
facility: 502.373.1003 Boehringer Ingelheim Investigational Site
city: Charleroi
country: Belgium
facility: 502.373.1017 Boehringer Ingelheim Investigational Site
city: Genk
country: Belgium
facility: 502.373.1009 Boehringer Ingelheim Investigational Site
city: Godinne
country: Belgium
facility: 502.373.1018 Boehringer Ingelheim Investigational Site
city: Haine-Saint-Paul
country: Belgium
facility: 502.373.1011 Boehringer Ingelheim Investigational Site
city: Haine-Saint-Paul
country: Belgium
facility: 502.373.1019 Boehringer Ingelheim Investigational Site
city: Hasselt
country: Belgium
facility: 502.373.1007 Boehringer Ingelheim Investigational Site
city: Leuven
country: Belgium
facility: 502.373.1000 Boehringer Ingelheim Investigational Site
city: Mechelen
country: Belgium
facility: 502.373.1020 Boehringer Ingelheim Investigational Site
city: Mol
country: Belgium
facility: 502.373.1006 Boehringer Ingelheim Investigational Site
city: Roeselare
country: Belgium
facility: 502.373.1028 Boehringer Ingelheim Investigational Site
city: Seraing
country: Belgium
facility: 502.373.1014 Boehringer Ingelheim Investigational Site
city: Turnhout
country: Belgium
facility: 502.373.1002 Boehringer Ingelheim Investigational Site
city: Turnhout
country: Belgium
facility: 502.373.1010 Boehringer Ingelheim Investigational Site
city: Woluwé-Saint-Lambert
country: Belgium
facility: 502.373.1025 Boehringer Ingelheim Investigational Site
city: Belo Horizonte
country: Brazil
facility: 502.373.405 Boehringer Ingelheim Investigational Site
city: Belo Horizonte
country: Brazil
facility: 502.373.412 Boehringer Ingelheim Investigational Site
city: Belo Horizonte
country: Brazil
facility: 502.373.426 Boehringer Ingelheim Investigational Site
city: Botucatu -
country: Brazil
facility: 502.373.418 Boehringer Ingelheim Investigational Site
city: Campinas
country: Brazil
facility: 502.373.407 Boehringer Ingelheim Investigational Site
city: Campinas
country: Brazil
facility: 502.373.419 Boehringer Ingelheim Investigational Site
city: Cerqueira César - São Paulo
country: Brazil
facility: 502.373.425 Boehringer Ingelheim Investigational Site
city: Curitiba
country: Brazil
facility: 502.373.406 Boehringer Ingelheim Investigational Site
city: Goiania
country: Brazil
facility: 502.373.411 Boehringer Ingelheim Investigational Site
city: Marília
country: Brazil
facility: 502.373.403 Boehringer Ingelheim Investigational Site
city: Pelotas
country: Brazil
facility: 502.373.400 Boehringer Ingelheim Investigational Site
city: Porto Alegre - Rs
country: Brazil
facility: 502.373.415 Boehringer Ingelheim Investigational Site
city: Porto Alegre
country: Brazil
facility: 502.373.416 Boehringer Ingelheim Investigational Site
city: Porto Alegre
country: Brazil
facility: 502.373.417 Boehringer Ingelheim Investigational Site
city: Ribeirao Preto
country: Brazil
facility: 502.373.420 Boehringer Ingelheim Investigational Site
city: Rio de Janeiro - Rj
country: Brazil
facility: 502.373.413 Boehringer Ingelheim Investigational Site
city: Rio de Janeiro
country: Brazil
facility: 502.373.414 Boehringer Ingelheim Investigational Site
city: Salvador
country: Brazil
facility: 502.373.409 Boehringer Ingelheim Investigational Site
city: Salvador
country: Brazil
facility: 502.373.410 Boehringer Ingelheim Investigational Site
city: Santa Catalina
country: Brazil
facility: 502.373.404 Boehringer Ingelheim Investigational Site
city: Sao Jose do Rio Preto
country: Brazil
facility: 502.373.421 Boehringer Ingelheim Investigational Site
city: Sao Paulo
country: Brazil
facility: 502.373.422 Boehringer Ingelheim Investigational Site
city: São Paulo
country: Brazil
facility: 502.373.402 Boehringer Ingelheim Investigational Site
city: São Paulo
country: Brazil
facility: 502.373.408 Boehringer Ingelheim Investigational Site
city: São Paulo
country: Brazil
facility: 502.373.424 Boehringer Ingelheim Investigational Site
city: Vila Clementino, São Paulo
country: Brazil
facility: 502.373.423 Boehringer Ingelheim Investigational Site
city: Calgary
country: Canada
facility: 502.373.0001 C849 Division of Cardiology, Foothills Medical Centre
state: Alberta
city: Calgary
country: Canada
facility: 502.373.0071 Peter Lougheed Centre
state: Alberta
city: Edmonton
country: Canada
facility: 502.373.0020 CHA/University Hospital
state: Alberta
city: Campbell river
country: Canada
facility: 502.373.0073 Alder Medical Centre
state: British Columbia
city: Coquitlam
country: Canada
facility: 502.373.0062 Gain Medical Centre
state: British Columbia
city: Kelowna
country: Canada
facility: 502.373.0046 Interior Clinical Research Consultants Ltd
state: British Columbia
city: New Westminster
country: Canada
facility: 502.373.0038 New West Cardiac Research
state: British Columbia
city: North Vancouver
country: Canada
facility: 502.373.0048 Suite 100
state: British Columbia
city: Penticton
country: Canada
facility: 502.373.0002 Penticton Regional Hospital
state: British Columbia
city: Vancouver
country: Canada
facility: 502.373.0009 Vancouver Hospital
state: British Columbia
city: Victoria
country: Canada
facility: 502.373.0003 Discovery Clinical Services Ltd
state: British Columbia
city: St. Pierre
country: Canada
facility: 502.373.0050 St. Pierre Medical Clinic
state: Manitoba
city: Winnipeg
country: Canada
facility: 502.373.0077 Health Science Centre Diabetes Research Group
state: Manitoba
city: ST John's
country: Canada
facility: 502.373.0005 Dr. Jeffrey Hiscock
state: Newfoundland and Labrador
city: St. John's
country: Canada
facility: 502.373.0006 The General Hospital
state: Newfoundland and Labrador
city: Antigonish
country: Canada
facility: 502.373.0056 Antigonish Clinical Trials
state: Nova Scotia
city: Halifax
country: Canada
facility: 502.373.0045 Queen Elizabeth II HSC
state: Nova Scotia
city: Brampton
country: Canada
facility: 502.373.0031 Brampton Research Associates
state: Ontario
city: Hamilton
country: Canada
facility: 502.373.0011 St. Joseph's Hospital Cardiac Research
state: Ontario
city: Hamilton
country: Canada
facility: 502.373.0034 HGH McMaster Clinic
state: Ontario
city: Hamilton
country: Canada
facility: 502.373.0035 Hamilton Medical Research
state: Ontario
city: Hamilton
country: Canada
facility: 502.373.0064 Chedoke Hospital
state: Ontario
city: Hamilton
country: Canada
facility: 502.373.0082 3U4, McMaster University Medical Centre
state: Ontario
city: Hamilton
country: Canada
facility: 502.373.0085 HGH McMaster Clinic
state: Ontario
city: London
country: Canada
facility: 502.373.0024 London HSC - University Hospital
state: Ontario
city: Mississauga
country: Canada
facility: 502.373.0044 Mississauga Clinical Research Centre
state: Ontario
city: New Westminster
country: Canada
facility: 502.373.0043 Fraser Clinical Trial Inc
state: Ontario
city: Newmarket
country: Canada
facility: 502.373.0032 New Market Cardiology Research Grp
state: Ontario
city: Niagara Falls
country: Canada
facility: 502.373.0037 Niagara Falls Medical Centre
state: Ontario
city: Orleans
country: Canada
facility: 502.373.0054 Orleans Medical-Dental Centre
state: Ontario
city: Oshawa
country: Canada
facility: 502.373.0058 Medical Sciences Building
state: Ontario
city: Oshawa
country: Canada
facility: 502.373.0063 Paradigm Clinical Trials
state: Ontario
city: Ottawa
country: Canada
facility: 502.373.0029 Riverside Professional Building
state: Ontario
city: Ottawa
country: Canada
facility: 502.373.0051 Merivale Cardiovascular Consultants
state: Ontario
city: Rexdale
country: Canada
facility: 502.373.0040 Etobicok Cardiology
state: Ontario
city: Sault Ste Marie
country: Canada
facility: 502.373.0023 Group Health Centre - Clinical Trials
state: Ontario
city: Scarborough
country: Canada
facility: 502.373.0039 Scarborough Cardiology Research
state: Ontario
city: Sudbury
country: Canada
facility: 502.373.0007 Sudbury Cardiac Research
state: Ontario
city: Thunder Bay
country: Canada
facility: 502.373.0061 CLIKS Medical Research Corp
state: Ontario
city: Toronto
country: Canada
facility: 502.373.0042 Sunnybrook & Woman's College Health Science Centre
state: Ontario
city: Toronto
country: Canada
facility: 502.373.0083 St. Michael's Hospital
state: Ontario
city: Willowdale
country: Canada
facility: 502.373.0052 Dr. Bruce Lubelsky
state: Ontario
city: Windsor
country: Canada
facility: 502.373.0008 Windsor Health Clinic
state: Ontario
city: Fleurimont
country: Canada
facility: 502.373.0081 Centre de recherche clinique, CUSE 3001
state: Quebec
city: Gatineau
country: Canada
facility: 502.373.0076 Centre Hospitalier de Vallees de l'Outaouais Gatineau
state: Quebec
city: Laval
country: Canada
facility: 502.373.0057 Centre De Recherche Clinique
state: Quebec
city: Levis
country: Canada
facility: 502.373.0033 Clinique de Cardiologie de Levis
state: Quebec
city: Longueuil
country: Canada
facility: 502.373.0010 Recherche Invascor
state: Quebec
city: Longueuil
country: Canada
facility: 502.373.0013 Suite 170
state: Quebec
city: Longueuil
country: Canada
facility: 502.373.0014 Via Car Recherche Clinique Inc
state: Quebec
city: Longueuil
country: Canada
facility: 502.373.0015 C/O Peter Carmichael
state: Quebec
city: Longueuil
country: Canada
facility: 502.373.0016 Suite 170
state: Quebec
city: Longueuil
country: Canada
facility: 502.373.0017 Suite 170
state: Quebec
city: Longueuil
country: Canada
facility: 502.373.0086 Via Car Recherche Clinique Inc
state: Quebec
city: Montreal
country: Canada
facility: 502.373.0018 Montreal Heart Institute
state: Quebec
city: Montreal
country: Canada
facility: 502.373.0021 Medi - recherche Inc.
state: Quebec
city: Montreal
country: Canada
facility: 502.373.0022 CHUM - Hotel Dieu
state: Quebec
city: Montreal
country: Canada
facility: 502.373.0025 Hopital Maisonneuve Rosemont
state: Quebec
city: Montreal
country: Canada
facility: 502.373.0079 Jewish General Hospital
state: Quebec
city: St George de Beauce
country: Canada
facility: 502.373.0027 Ctr Hospitalier Beauce Etchemin
state: Quebec
city: Ste-Foy
country: Canada
facility: 502.373.0012 Hopital Laval - Institute Cardiologie de Quebec
state: Quebec
city: Terrebonne
country: Canada
facility: 502.373.0026 Centre hospitalier Pierre-Le Gardeur
state: Quebec
city: Thetford Mines
country: Canada
facility: 502.373.0072 Chra
state: Quebec
city: Saskatoon
country: Canada
facility: 502.373.0053 Mount Royal Clinic
state: Saskatchewan
city: Saskatoon
country: Canada
facility: 502.373.0055 Specialists - Internal Medicine
state: Saskatchewan
city: Saskatoon
country: Canada
facility: 502.373.0066 SDRI - University of Saskatchewan
state: Saskatchewan
city: Saskatoon
country: Canada
facility: 502.373.0067 SDRI - University of Saskatchewan
state: Saskatchewan
city: Saskatoon
country: Canada
facility: 502.373.0068 SDRI - University of Saskatchewan
state: Saskatchewan
city: Saskatoon
country: Canada
facility: 502.373.0070 SDRI - University of Saskatchewan
state: Saskatchewan
city: Manitoba
country: Canada
facility: 502.373.0030 Portage Clinical Studies
city: Quebec
country: Canada
facility: 502.373.0028 Hop. Du St. Sacrement
city: Quebec
country: Canada
facility: 502.373.0041 Recherches Clinicar Inc.
city: Quebec
country: Canada
facility: 502.373.0080 Polyclinique vasculaire Centre hospitalier universitaire de
city: Quebec
country: Canada
facility: 502.373.0084 CHA-Hopital de l'Efant-Jesus
city: Beijing
country: China
facility: 502.373.0601 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 502.373.0602 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 502.373.0603 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 502.373.0604 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 502.373.0605 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 502.373.0606 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 502.373.0607 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 502.373.0621 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 502.373.0622 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 502.373.0623 Boehringer Ingelheim Investigational Site
city: Beijing
country: China
facility: 502.373.0626 Boehringer Ingelheim Investigational Site
city: Changsha
country: China
facility: 502.373.0616 Boehringer Ingelheim Investigational Site
city: Chengdu
country: China
facility: 502.373.0613 Boehringer Ingelheim Investigational Site
city: Chengdu
country: China
facility: 502.373.0625 Boehringer Ingelheim Investigational Site
city: Guangzhou
country: China
facility: 502.373.0620 Boehringer Ingelheim Investigational Site
city: Harbin
country: China
facility: 502.373.0612 Boehringer Ingelheim Investigational Site
city: HeBei Province
country: China
facility: 502.373.0634 Boehringer Ingelheim Investigational Site
city: Henan Province
country: China
facility: 502.373.0624 Boehringer Ingelheim Investigational Site
city: Hubei Province
country: China
facility: 502.373.0627 Boehringer Ingelheim Investigational Site
city: Nanjing
country: China
facility: 502.373.0614 Boehringer Ingelheim Investigational Site
city: QingDao
country: China
facility: 502.373.0629 Boehringer Ingelheim Investigational Site
city: ShanDong Province
country: China
facility: 502.373.0632 Boehringer Ingelheim Investigational Site
city: ShanDong Province
country: China
facility: 502.373.0633 Boehringer Ingelheim Investigational Site
city: Shanghai
country: China
facility: 502.373.0617 Boehringer Ingelheim Investigational Site
city: Shanghai
country: China
facility: 502.373.0618 Boehringer Ingelheim Investigational Site
city: Shanghai
country: China
facility: 502.373.0619 Boehringer Ingelheim Investigational Site
city: Shen Yang
country: China
facility: 502.373.0628 Boehringer Ingelheim Investigational Site
city: Shijiazhuang
country: China
facility: 502.373.0611 Boehringer Ingelheim Investigational Site
city: Tianjin
country: China
facility: 502.373.0615 Boehringer Ingelheim Investigational Site
city: Tianjin
country: China
facility: 502.373.0631 Boehringer Ingelheim Investigational Site
city: Weizikeng
country: China
facility: 502.373.0630 Boehringer Ingelheim Investigational Site
city: Wuhan
country: China
facility: 502.373.0608 Boehringer Ingelheim Investigational Site
city: Zhenzhou
country: China
facility: 502.373.0610 Boehringer Ingelheim Investigational Site
city: Brno
country: Czech Republic
facility: 502.373.1053 Boehringer Ingelheim Investigational Site
city: Havirov
country: Czech Republic
facility: 502.373.1060 Boehringer Ingelheim Investigational Site
city: Kladno
country: Czech Republic
facility: 502.373.1055 Boehringer Ingelheim Investigational Site
city: Mlada Boleslav
country: Czech Republic
facility: 502.373.1059 Boehringer Ingelheim Investigational Site
city: Plzen
country: Czech Republic
facility: 502.373.1061 Boehringer Ingelheim Investigational Site
city: Prague 5
country: Czech Republic
facility: 502.373.1051 Boehringer Ingelheim Investigational Site
city: Prague
country: Czech Republic
facility: 502.373.1057 Boehringer Ingelheim Investigational Site
city: Praha 2
country: Czech Republic
facility: 502.373.1062 Boehringer Ingelheim Investigational Site
city: Pribram 1
country: Czech Republic
facility: 502.373.1056 Boehringer Ingelheim Investigational Site
city: Usti nad Orlici
country: Czech Republic
facility: 502.373.1058 Boehringer Ingelheim Investigational Site
city: Aalborg
country: Denmark
facility: 502.373.1450 Boehringer Ingelheim Investigational Site
city: Aarhus C
country: Denmark
facility: 502.373.1453 Boehringer Ingelheim Investigational Site
city: Frederiksberg C
country: Denmark
facility: 502.373.1459 Boehringer Ingelheim Investigational Site
city: Frederiksberg
country: Denmark
facility: 502.373.1455 Boehringer Ingelheim Investigational Site
city: Helsingoer
country: Denmark
facility: 502.373.1460 Boehringer Ingelheim Investigational Site
city: Hilleroed
country: Denmark
facility: 502.373.1458 Boehringer Ingelheim Investigational Site
city: Holbaek
country: Denmark
facility: 502.373.1451 Boehringer Ingelheim Investigational Site
city: Hvidovre
country: Denmark
facility: 502.373.1452 Boehringer Ingelheim Investigational Site
city: Kjellerup
country: Denmark
facility: 502.373.1461 Boehringer Ingelheim Investigational Site
city: Randers
country: Denmark
facility: 502.373.1456 Boehringer Ingelheim Investigational Site
city: Slagelse
country: Denmark
facility: 502.373.1457 Boehringer Ingelheim Investigational Site
city: Svendborg
country: Denmark
facility: 502.373.1454 Boehringer Ingelheim Investigational Site
city: Helsinki
country: Finland
facility: 502.373.1470 Boehringer Ingelheim Investigational Site
city: Helsinki
country: Finland
facility: 502.373.1473 Boehringer Ingelheim Investigational Site
city: Hämeenlinna
country: Finland
facility: 502.373.1486 Boehringer Ingelheim Investigational Site
city: Jyväskylä
country: Finland
facility: 502.373.1479 Boehringer Ingelheim Investigational Site
city: Kuopio
country: Finland
facility: 502.373.1488 Boehringer Ingelheim Investigational Site
city: Kuusankoski
country: Finland
facility: 502.373.1481 Boehringer Ingelheim Investigational Site
city: Liperi
country: Finland
facility: 502.373.1487 Boehringer Ingelheim Investigational Site
city: Oulun kaupunki
country: Finland
facility: 502.373.1475 Boehringer Ingelheim Investigational Site
city: Turku
country: Finland
facility: 502.373.1471 Boehringer Ingelheim Investigational Site
city: Vantaa
country: Finland
facility: 502.373.1485 Boehringer Ingelheim Investigational Site
city: Albens
country: France
facility: 502.373.1093 Cabinet Médical
city: Beziers
country: France
facility: 502.373.1090 Cabinet Médical
city: Bourges
country: France
facility: 502.373.1075 Cabinet Médical
city: Broglie
country: France
facility: 502.373.1091 Cabinet Médical
city: Castelnaudary
country: France
facility: 502.373.1097 Cabinet Médical
city: Gemenos
country: France
facility: 502.373.1089 Cabinet Médical
city: Husseren Wesserlin
country: France
facility: 502.373.1099 Cabinet Médical
city: Hyeres
country: France
facility: 502.373.1094 Cabinet Médical
city: L'Aigle
country: France
facility: 502.373.1078 Cabinet Médical des Tanneurs
city: La Rochelle
country: France
facility: 502.373.1096 Cabinet Médical
city: Le Pradet
country: France
facility: 502.373.1081 Cabinet Médical
city: Murs Erigne
country: France
facility: 502.373.1083 Cabinet Médical
city: Nantes
country: France
facility: 502.373.1084 Cabinet Médical
city: Nantes
country: France
facility: 502.373.1086 Cabinet Médical
city: Niort
country: France
facility: 502.373.1080 Cabinet Médical
city: Ortez
country: France
facility: 502.373.1095 Cabinet Médical
city: Paris
country: France
facility: 502.373.1079 Cabinet Médical
city: Rennes
country: France
facility: 502.373.1088 Cabinet Médical
city: Rosiers d'Egletons
country: France
facility: 502.373.1098 Cabinet Médical
city: Saint Julien des Landes
country: France
facility: 502.373.1085 Cabinet Médical
city: Saint Martin dHyeres
country: France
facility: 502.373.1076 Cabinet Médical La Grande Ramée
city: Saint Pierre de Chandieu
country: France
facility: 502.373.1092 Cabinet Médical de St Pierre
city: Saint Romain sur Cher
country: France
facility: 502.373.1077 Cabinet Médical
city: Strasbourg
country: France
facility: 502.373.1087 Cabinet Médical
city: Tours
country: France
facility: 502.373.1082 Cabinet Médical
city: Bad Lausick
country: Germany
facility: 502.373.1164 Boehringer Ingelheim Investigational Site
city: Bad Lauterberg
country: Germany
facility: 502.373.1166 Boehringer Ingelheim Investigational Site
city: Bad Mergentheim
country: Germany
facility: 502.373.1138 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 502.373.1156 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 502.373.1160 Boehringer Ingelheim Investigational Site
city: Berlin
country: Germany
facility: 502.373.1161 Boehringer Ingelheim Investigational Site
city: Bielefeld
country: Germany
facility: 502.373.1144 Boehringer Ingelheim Investigational Site
city: Dessau
country: Germany
facility: 502.373.1152 Boehringer Ingelheim Investigational Site
city: Dortmund
country: Germany
facility: 502.373.1139 Boehringer Ingelheim Investigational Site
city: Dortmund
country: Germany
facility: 502.373.1159 Boehringer Ingelheim Investigational Site
city: Dresden
country: Germany
facility: 502.373.1136 Boehringer Ingelheim Investigational Site
city: Eberswalde
country: Germany
facility: 502.373.1145 Boehringer Ingelheim Investigational Site
city: Erlangen
country: Germany
facility: 502.373.1155 Boehringer Ingelheim Investigational Site
city: Essen
country: Germany
facility: 502.373.1157 Boehringer Ingelheim Investigational Site
city: Haag
country: Germany
facility: 502.373.1153 Boehringer Ingelheim Investigational Site
city: Hamburg
country: Germany
facility: 502.373.1148 Boehringer Ingelheim Investigational Site
city: Heidelberg
country: Germany
facility: 502.373.1132 Boehringer Ingelheim Investigational Site
city: Homburg/Saar
country: Germany
facility: 502.373.1131 Boehringer Ingelheim Investigational Site
city: Karlsburg
country: Germany
facility: 502.373.1147 Boehringer Ingelheim Investigational Site
city: Kelkheim
country: Germany
facility: 502.373.1154 Boehringer Ingelheim Investigational Site
city: Köln
country: Germany
facility: 502.373.1137 Boehringer Ingelheim Investigational Site
city: Künzing
country: Germany
facility: 502.373.1142 Boehringer Ingelheim Investigational Site
city: Lübeck
country: Germany
facility: 502.373.1165 Boehringer Ingelheim Investigational Site
city: Mainz
country: Germany
facility: 502.373.1134 Boehringer Ingelheim Investigational Site
city: Melsungen
country: Germany
facility: 502.373.1133 Boehringer Ingelheim Investigational Site
city: München
country: Germany
facility: 502.373.1146 Boehringer Ingelheim Investigational Site
city: Offenbach am Main
country: Germany
facility: 502.373.1149 Boehringer Ingelheim Investigational Site
city: Riesa
country: Germany
facility: 502.373.1162 Boehringer Ingelheim Investigational Site
city: Rostock
country: Germany
facility: 502.373.1140 Boehringer Ingelheim Investigational Site
city: Sindelfingen
country: Germany
facility: 502.373.1150 Boehringer Ingelheim Investigational Site
city: Starnberg
country: Germany
facility: 502.373.1163 Boehringer Ingelheim Investigational Site
city: Stuttgart
country: Germany
facility: 502.373.1158 Boehringer Ingelheim Investigational Site
city: Timmendorfer Strand
country: Germany
facility: 502.373.1167 Boehringer Ingelheim Investigational Site
city: Wiesbaden
country: Germany
facility: 502.373.1135 Boehringer Ingelheim Investigational Site
city: Witten
country: Germany
facility: 502.373.1141 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 502.373.1200 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 502.373.1203 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 502.373.1206 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 502.373.1207 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 502.373.1208 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 502.373.1214 Boehringer Ingelheim Investigational Site
city: Elefsina
country: Greece
facility: 502.373.1209 Boehringer Ingelheim Investigational Site
city: Goudi/ Athens
country: Greece
facility: 502.373.1211 Boehringer Ingelheim Investigational Site
city: Ioannina
country: Greece
facility: 502.373.1201 Boehringer Ingelheim Investigational Site
city: Kavala,greece
country: Greece
facility: 502.373.1210 Boehringer Ingelheim Investigational Site
city: Korinthos
country: Greece
facility: 502.373.1224 Boehringer Ingelheim Investigational Site
city: Melissia, Athens
country: Greece
facility: 502.373.1202 Boehringer Ingelheim Investigational Site
city: Thessaloniki
country: Greece
facility: 502.373.1205 Boehringer Ingelheim Investigational Site
city: Thessaloniki
country: Greece
facility: 502.373.1213 Boehringer Ingelheim Investigational Site
city: Veria
country: Greece
facility: 502.373.1204 Boehringer Ingelheim Investigational Site
city: Hong Kong
country: Hong Kong
facility: 502.373.0676 Boehringer Ingelheim Investigational Site
city: Hong Kong
country: Hong Kong
facility: 502.373.0677 Boehringer Ingelheim Investigational Site
city: Hong Kong
country: Hong Kong
facility: 502.373.0680 Boehringer Ingelheim Investigational Site
city: Hong Kong
country: Hong Kong
facility: 502.373.0681 Boehringer Ingelheim Investigational Site
city: Hong Kong
country: Hong Kong
facility: 502.373.0685 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 502.373.1227 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 502.373.1230 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 502.373.1231 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 502.373.1232 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 502.373.1233 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 502.373.1235 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 502.373.1237 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 502.373.1239 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 502.373.1242 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 502.373.1244 Boehringer Ingelheim Investigational Site
city: Debrecen
country: Hungary
facility: 502.373.1236 Boehringer Ingelheim Investigational Site
city: Debrecen
country: Hungary
facility: 502.373.1240 Boehringer Ingelheim Investigational Site
city: Kecskemet
country: Hungary
facility: 502.373.1228 Boehringer Ingelheim Investigational Site
city: Nyiregyhaza
country: Hungary
facility: 502.373.1241 Boehringer Ingelheim Investigational Site
city: Pecs
country: Hungary
facility: 502.373.1226 Boehringer Ingelheim Investigational Site
city: Siofok
country: Hungary
facility: 502.373.1229 Boehringer Ingelheim Investigational Site
city: Szeged
country: Hungary
facility: 502.373.1238 Boehringer Ingelheim Investigational Site
city: Szekesfehervar
country: Hungary
facility: 502.373.1225 Boehringer Ingelheim Investigational Site
city: Tatabanya
country: Hungary
facility: 502.373.1234 Boehringer Ingelheim Investigational Site
city: Veszprem
country: Hungary
facility: 502.373.1243 Boehringer Ingelheim Investigational Site
city: Dublin 24
country: Ireland
facility: 502.373.1717 Adelaide & Meath Hospitals
city: Dublin 8
country: Ireland
facility: 502.373.1714 Dept. of Clinical Pharmacology
city: Dublin 9
country: Ireland
facility: 502.373.1719 Pulmonary Function Laboratory
city: Mallow
country: Ireland
facility: 502.373.1720 Mallow General Hospital
city: Ascoli Piceno
country: Italy
facility: 502.373.1257 Ospedale "Mazzoni"
city: Bentivoglio (BO)
country: Italy
facility: 502.373.1259 Ospedale di Bentivoglio
city: Bologna
country: Italy
facility: 502.373.1255 Ospedale "S. Orsola Malpighi"
city: Bologna
country: Italy
facility: 502.373.1278 Ospedale Bellaria
city: Brescia
country: Italy
facility: 502.373.1275 A.O. Spedali Civili di Brescia -Univ. degli studi di Brescia
city: Casarano (LE)
country: Italy
facility: 502.373.1261 Ospedale Civile di Casarano
city: Caserta
country: Italy
facility: 502.373.1252 Azienda Ospedaliera di Caserta
city: Città della Pieve (PG)
country: Italy
facility: 502.373.1254 Ospedale di Città della Pieve
city: Ferrara
country: Italy
facility: 502.373.1262 Arcispedale "S. Anna"
city: Monfalcone (go)
country: Italy
facility: 502.373.1250 Ospedale Civile "S. Polo"
city: Napoli
country: Italy
facility: 502.373.1266 Azienda Universitaria Policlinico "Federico II"
city: Napoli
country: Italy
facility: 502.373.1267 Azienda Universitaria Policlinico II
city: Napoli
country: Italy
facility: 502.373.1269 Università Federico II
city: Napoli
country: Italy
facility: 502.373.1279 Asl Na 1
city: Palermo
country: Italy
facility: 502.373.1264 Presidio Ospedaliero "Villa Sofia"
city: Pavia
country: Italy
facility: 502.373.1265 IRCCS - Policlinico S. Matteo
city: Perugia
country: Italy
facility: 502.373.1251 Policlinico Monteluce
city: Perugia
country: Italy
facility: 502.373.1258 Ospedale "R. Silvestrini"
city: Perugia
country: Italy
facility: 502.373.1274 Ospedale "R. Silvestrini"
city: Pozzilli (IS)
country: Italy
facility: 502.373.1253 Istituto di Ricovero a Carattere Scientifico Neuromed- IRCCS
city: Roma
country: Italy
facility: 502.373.1263 Policlinico Umberto I
city: Roma
country: Italy
facility: 502.373.1268 Ospedale "S. Spirito"
city: Roma
country: Italy
facility: 502.373.1270 Policlinico di Tor Vergata
city: Roma
country: Italy
facility: 502.373.1273 A.O. "S. Camillo de Lellis"
city: S. Pietro Vernotico (BR)
country: Italy
facility: 502.373.1260 Ospedale "N. Melli"
city: Sassari
country: Italy
facility: 502.373.1256 Ospedale Civile SS. Annunziata - USL 1
city: Torino
country: Italy
facility: 502.373.1277 A.S.O. "S. Giovanni Battista"
city: Varese
country: Italy
facility: 502.373.1272 Ospedale di Circolo di Varese
city: Venezia
country: Italy
facility: 502.373.1271 Ospedale Civile
city: Viterbo
country: Italy
facility: 502.373.1276 Ospedale Belcolle
city: Incheon
country: Korea, Republic of
facility: 502.373.0763 Boehringer Ingelheim Investigational Site
city: Kwang-ju
country: Korea, Republic of
facility: 502.373.0764 Boehringer Ingelheim Investigational Site
city: Pusan
country: Korea, Republic of
facility: 502.373.0755 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 502.373.0750 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 502.373.0753 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 502.373.0756 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 502.373.0757 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 502.373.0760 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 502.373.0761 Boehringer Ingelheim Investigational Site
city: Taegu
country: Korea, Republic of
facility: 502.373.0754 Boehringer Ingelheim Investigational Site
city: Johor Baharu
country: Malaysia
facility: 502.373.0736 Boehringer Ingelheim Investigational Site
city: Kelantan Darul Naim
country: Malaysia
facility: 502.373.2707 Boehringer Ingelheim Investigational Site
city: Kelantan
country: Malaysia
facility: 502.373.0739 Boehringer Ingelheim Investigational Site
city: Kuala Lumpur
country: Malaysia
facility: 502.373.0732 Boehringer Ingelheim Investigational Site
city: Kuala Lumpur
country: Malaysia
facility: 502.373.0734 Boehringer Ingelheim Investigational Site
city: Penang
country: Malaysia
facility: 502.373.0733 Boehringer Ingelheim Investigational Site
city: Putrajaya
country: Malaysia
facility: 502.373.0731 Boehringer Ingelheim Investigational Site
city: Selangor
country: Malaysia
facility: 502.373.60001 Boehringer Ingelheim Investigational Site
city: Guadalajara
country: Mexico
facility: 502.373.0450 Boehringer Ingelheim Investigational Site
city: Guadalajara
country: Mexico
facility: 502.373.0451 Boehringer Ingelheim Investigational Site
city: Guadalajara
country: Mexico
facility: 502.373.0452 Boehringer Ingelheim Investigational Site
city: Guadalajara
country: Mexico
facility: 502.373.0459 Boehringer Ingelheim Investigational Site
city: Guadalajara
country: Mexico
facility: 502.373.0460 Boehringer Ingelheim Investigational Site
city: Guadalajara
country: Mexico
facility: 502.373.0461 Boehringer Ingelheim Investigational Site
city: Guadalajara
country: Mexico
facility: 502.373.0470 Boehringer Ingelheim Investigational Site
city: Mexico
country: Mexico
facility: 502.373.0457 Boehringer Ingelheim Investigational Site
city: Mexico
country: Mexico
facility: 502.373.0458 Boehringer Ingelheim Investigational Site
city: Monterrey
country: Mexico
facility: 502.373.0454 Boehringer Ingelheim Investigational Site
city: Zapopan
country: Mexico
facility: 502.373.0453 Boehringer Ingelheim Investigational Site
city: Zapopan
country: Mexico
facility: 502.373.0456 Boehringer Ingelheim Investigational Site
city: Amsterdam
country: Netherlands
facility: 502.373.1309 Boehringer Ingelheim Investigational Site
city: Beverwijk
country: Netherlands
facility: 502.373.1305 Boehringer Ingelheim Investigational Site
city: Den Bosch
country: Netherlands
facility: 502.373.1313 Boehringer Ingelheim Investigational Site
city: Den Haag
country: Netherlands
facility: 502.373.1312 Boehringer Ingelheim Investigational Site
city: Doetinchem
country: Netherlands
facility: 502.373.1302 Boehringer Ingelheim Investigational Site
city: Drachten
country: Netherlands
facility: 502.373.1304 Boehringer Ingelheim Investigational Site
city: Eindhoven
country: Netherlands
facility: 502.373.1301 Boehringer Ingelheim Investigational Site
city: Ermelo
country: Netherlands
facility: 502.373.1318 Boehringer Ingelheim Investigational Site
city: Ewijk
country: Netherlands
facility: 502.373.1320 Boehringer Ingelheim Investigational Site
city: Hengelo
country: Netherlands
facility: 502.373.1310 Boehringer Ingelheim Investigational Site
city: Hoorn
country: Netherlands
facility: 502.373.1303 Boehringer Ingelheim Investigational Site
city: Huizen
country: Netherlands
facility: 502.373.1322 Boehringer Ingelheim Investigational Site
city: Lichtenvoorde
country: Netherlands
facility: 502.373.1300 Boehringer Ingelheim Investigational Site
city: Losser
country: Netherlands
facility: 502.373.1323 Boehringer Ingelheim Investigational Site
city: Nieuwegein
country: Netherlands
facility: 502.373.1307 Boehringer Ingelheim Investigational Site
city: Rijswijk
country: Netherlands
facility: 502.373.1317 Boehringer Ingelheim Investigational Site
city: Roelofarendsveen
country: Netherlands
facility: 502.373.1319 Boehringer Ingelheim Investigational Site
city: Rotterdam
country: Netherlands
facility: 502.373.1308 Boehringer Ingelheim Investigational Site
city: Spijkenisse
country: Netherlands
facility: 502.373.1321 Boehringer Ingelheim Investigational Site
city: Stadskanaal
country: Netherlands
facility: 502.373.1311 Boehringer Ingelheim Investigational Site
city: Tilburg
country: Netherlands
facility: 502.373.1314 Boehringer Ingelheim Investigational Site
city: Utrecht
country: Netherlands
facility: 502.373.1316 Boehringer Ingelheim Investigational Site
city: Velp
country: Netherlands
facility: 502.373.1315 Boehringer Ingelheim Investigational Site
city: Auckland 3
country: New Zealand
facility: 502.373.0502 Boehringer Ingelheim Investigational Site
city: Auckland
country: New Zealand
facility: 502.373.0500 Boehringer Ingelheim Investigational Site
city: Christchurch
country: New Zealand
facility: 502.373.0507 Boehringer Ingelheim Investigational Site
city: Hamiton
country: New Zealand
facility: 502.373.0504 Boehringer Ingelheim Investigational Site
city: Hasting
country: New Zealand
facility: 502.373.0506 Boehringer Ingelheim Investigational Site
city: Otahuhu Auckland
country: New Zealand
facility: 502.373.0501 Middlemore Hospital
city: Takapuna Auckland
country: New Zealand
facility: 502.373.0503 Boehringer Ingelheim Investigational Site
city: Tauranga
country: New Zealand
facility: 502.373.0505 Tauranga Study Centre
city: Fevik
country: Norway
facility: 502.373.20003 Boehringer Ingelheim Investigational Site
city: Nesttun
country: Norway
facility: 502.373.20004 Fana Hjertesenter
city: Stavanger
country: Norway
facility: 502.373.20001 Stavanger Universitetssykehus
city: Tvedestrand
country: Norway
facility: 502.373.20002 Tvedestrand Legesenter
city: Tønsberg
country: Norway
facility: 502.373.20005 Sykehuset i Vestfold, Avd. Tønsberg
city: Cavite
country: Philippines
facility: 502.373.0702 De La Salle University Medical Center
city: Manila
country: Philippines
facility: 502.373.0700 Philippine General Hospital
city: Manila
country: Philippines
facility: 502.373.0701 Manila Doctors Hospital, Room 3 Annex
city: Pasig City
country: Philippines
facility: 502.373.0705 The Medical City
city: Quezon City
country: Philippines
facility: 502.373.0703 Philippine Heart Center
city: Quezon City
country: Philippines
facility: 502.373.0704 National Kidney & Transplant Institute, Room 821
city: Bydgoszcz
country: Poland
facility: 502.373.1354 Boehringer Ingelheim Investigational Site
city: Czestochowa
country: Poland
facility: 502.373.1366 Boehringer Ingelheim Investigational Site
city: Gdynia Redlowo
country: Poland
facility: 502.373.1365 Boehringer Ingelheim Investigational Site
city: Gdynia
country: Poland
facility: 502.373.1368 Boehringer Ingelheim Investigational Site
city: Grojec
country: Poland
facility: 502.373.1359 Boehringer Ingelheim Investigational Site
city: Grudziadz
country: Poland
facility: 502.373.1369 Boehringer Ingelheim Investigational Site
city: Inowroclaw
country: Poland
facility: 502.373.1375 Boehringer Ingelheim Investigational Site
city: Jaroslawiec
country: Poland
facility: 502.373.1360 Boehringer Ingelheim Investigational Site
city: Katowice
country: Poland
facility: 502.373.1372 Boehringer Ingelheim Investigational Site
city: Katowice
country: Poland
facility: 502.373.1376 Boehringer Ingelheim Investigational Site
city: Kielce
country: Poland
facility: 502.373.1361 Boehringer Ingelheim Investigational Site
city: Lodz
country: Poland
facility: 502.373.1358 Boehringer Ingelheim Investigational Site
city: Lubartow
country: Poland
facility: 502.373.1364 Boehringer Ingelheim Investigational Site
city: Lubin
country: Poland
facility: 502.373.1374 Boehringer Ingelheim Investigational Site
city: Nowy Sacz
country: Poland
facility: 502.373.1367 Boehringer Ingelheim Investigational Site
city: Piotrkow Trybunalski
country: Poland
facility: 502.373.1356 Boehringer Ingelheim Investigational Site
city: Poznan
country: Poland
facility: 502.373.1370 Boehringer Ingelheim Investigational Site
city: Ruda Slaska
country: Poland
facility: 502.373.1357 Boehringer Ingelheim Investigational Site
city: Skierniewice
country: Poland
facility: 502.373.1352 Boehringer Ingelheim Investigational Site
city: Tarnow
country: Poland
facility: 502.373.1362 Boehringer Ingelheim Investigational Site
city: Tomaszow Mazowiecki
country: Poland
facility: 502.373.1355 Boehringer Ingelheim Investigational Site
city: Torun
country: Poland
facility: 502.373.1353 Boehringer Ingelheim Investigational Site
city: Warsaw
country: Poland
facility: 502.373.1351 Boehringer Ingelheim Investigational Site
city: Warsaw
country: Poland
facility: 502.373.1363 Boehringer Ingelheim Investigational Site
city: Wegrow
country: Poland
facility: 502.373.1373 Boehringer Ingelheim Investigational Site
city: Almada
country: Portugal
facility: 502.373.1402 Hospital Garcia de Orta
city: Amadora
country: Portugal
facility: 502.373.1400 Hospital Fernando Fonseca
city: Carnaxide
country: Portugal
facility: 502.373.1411 Hospital de Santa Cruz
city: Coimbra
country: Portugal
facility: 502.373.1408 Hospitais da Universidade de Coimbra
city: Faro
country: Portugal
facility: 502.373.1406 Hospital Distrital de Faro Geral
city: Lisboa
country: Portugal
facility: 502.373.1403 Hospital de Santa Marta
city: Lisboa
country: Portugal
facility: 502.373.1409 Hospital de Santa Maria
city: Matosinhos
country: Portugal
facility: 502.373.1401 Unidade Local de Saúde de Matosinhos
city: Porto
country: Portugal
facility: 502.373.1410 Hospital de Santo António
city: Vila Nova de Gaia
country: Portugal
facility: 502.373.1407 Centro Hospitalar vila Nova de Gaia
city: Caguas
country: Puerto Rico
facility: 502.373.0215 Boehringer Ingelheim Investigational Site
city: Las Lomas
country: Puerto Rico
facility: 502.373.0267 Boehringer Ingelheim Investigational Site
city: Manati
country: Puerto Rico
facility: 502.373.0190 Boehringer Ingelheim Investigational Site
city: Orocovis
country: Puerto Rico
facility: 502.373.0198 Boehringer Ingelheim Investigational Site
city: Rio Piedras
country: Puerto Rico
facility: 502.373.0262 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 502.373.1425 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 502.373.1426 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 502.373.1427 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 502.373.1428 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 502.373.1429 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 502.373.1430 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 502.373.1433 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 502.373.1431 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 502.373.1432 Boehringer Ingelheim Investigational Site
city: Kuala Lumpur
country: Singapore
facility: 502.373.2706 Boehringer Ingelheim Investigational Site
city: Singapore
country: Singapore
facility: 502.373.0725 Boehringer Ingelheim Investigational Site
city: Singapore
country: Singapore
facility: 502.373.0726 Boehringer Ingelheim Investigational Site
city: Bratislava
country: Slovakia
facility: 502.373.1535 Boehringer Ingelheim Investigational Site
city: Kosice
country: Slovakia
facility: 502.373.1529 Boehringer Ingelheim Investigational Site
city: Kosice
country: Slovakia
facility: 502.373.1540 Boehringer Ingelheim Investigational Site
city: Nitra
country: Slovakia
facility: 502.373.1538 Boehringer Ingelheim Investigational Site
city: Rimavska Sobota
country: Slovakia
facility: 502.373.1545 Boehringer Ingelheim Investigational Site
city: Bellville
country: South Africa
facility: 502.373.1553 Boehringer Ingelheim Investigational Site
city: Bloemfontein
country: South Africa
facility: 502.373.1552 Boehringer Ingelheim Investigational Site
city: Cape Town
country: South Africa
facility: 502.373.1550 Boehringer Ingelheim Investigational Site
city: Cape Town
country: South Africa
facility: 502.373.1561 Boehringer Ingelheim Investigational Site
city: Congella
country: South Africa
facility: 502.373.1554 Boehringer Ingelheim Investigational Site
city: Durban
country: South Africa
facility: 502.373.1551 Boehringer Ingelheim Investigational Site
city: Fiachrdtpark, Bloemfontein
country: South Africa
facility: 502.373.1560 Boehringer Ingelheim Investigational Site
city: George East
country: South Africa
facility: 502.373.1563 Boehringer Ingelheim Investigational Site
city: Park Town West
country: South Africa
facility: 502.373.1555 Boehringer Ingelheim Investigational Site
city: Port Elizabeth
country: South Africa
facility: 502.373.1559 Boehringer Ingelheim Investigational Site
city: Port Elizabeth
country: South Africa
facility: 502.373.1562 Boehringer Ingelheim Investigational Site
city: Soweto
country: South Africa
facility: 502.373.1558 Boehringer Ingelheim Investigational Site
city: Sunninghill
country: South Africa
facility: 502.373.1557 Boehringer Ingelheim Investigational Site
city: Sunninghill
country: South Africa
facility: 502.373.1564 Boehringer Ingelheim Investigational Site
city: Vanderbijlpark
country: South Africa
facility: 502.373.1556 Boehringer Ingelheim Investigational Site
city: Alcorcón (Madrid)
country: Spain
facility: 502.373.1582 Boehringer Ingelheim Investigational Site
city: Alicante
country: Spain
facility: 502.373.1601 Boehringer Ingelheim Investigational Site
city: Barcelona
country: Spain
facility: 502.373.1586 Boehringer Ingelheim Investigational Site
city: Barcelona
country: Spain
facility: 502.373.1590 Boehringer Ingelheim Investigational Site
city: Barcelona
country: Spain
facility: 502.373.1597 Boehringer Ingelheim Investigational Site
city: Barcelona
country: Spain
facility: 502.373.1599 Boehringer Ingelheim Investigational Site
city: Burjasot (Valencia)
country: Spain
facility: 502.373.1595 Boehringer Ingelheim Investigational Site
city: Granada
country: Spain
facility: 502.373.1584 Boehringer Ingelheim Investigational Site
city: Granada
country: Spain
facility: 502.373.1585 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 502.373.1576 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 502.373.1578 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 502.373.1580 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 502.373.1589 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 502.373.1592 Boehringer Ingelheim Investigational Site
city: Murcia
country: Spain
facility: 502.373.1594 Boehringer Ingelheim Investigational Site
city: Málaga
country: Spain
facility: 502.373.1577 Boehringer Ingelheim Investigational Site
city: Málaga
country: Spain
facility: 502.373.1596 Boehringer Ingelheim Investigational Site
city: Santiago de Compostela
country: Spain
facility: 502.373.1579 Boehringer Ingelheim Investigational Site
city: Santiago de Compostela
country: Spain
facility: 502.373.1593 Boehringer Ingelheim Investigational Site
city: Santiago de Compostela
country: Spain
facility: 502.373.1598 Boehringer Ingelheim Investigational Site
city: Sevilla
country: Spain
facility: 502.373.1583 Boehringer Ingelheim Investigational Site
city: Valencia
country: Spain
facility: 502.373.1575 Boehringer Ingelheim Investigational Site
city: Valencia
country: Spain
facility: 502.373.1591 Boehringer Ingelheim Investigational Site
city: Göteborg
country: Sweden
facility: 502.373.1504 Capio Lundby sjukhus
city: Göteborg
country: Sweden
facility: 502.373.1509 Hjärtsektionen / Med.kliniken
city: Göteborg
country: Sweden
facility: 502.373.1514 Hjärt/Kärlforskn.enheten
city: Helsingborg
country: Sweden
facility: 502.373.1501 Hjaertmottagningen
city: Järfälla
country: Sweden
facility: 502.373.1505 Jakobsbergs sjukhus
city: Malmoe
country: Sweden
facility: 502.373.1502 Borgmästargaardens Läkarmottagning
city: Malmö
country: Sweden
facility: 502.373.1506 Hjärtmottagningen
city: Malmö
country: Sweden
facility: 502.373.1507 Kardiologiska kliniken
city: Malmö
country: Sweden
facility: 502.373.1508 Kolgahuset Läkargrupp
city: Sjuntorp
country: Sweden
facility: 502.373.1511 Sjuntorps Vaardcentral
city: Trollhättan
country: Sweden
facility: 502.373.1503 Källtorps Vaardcentral
city: Vännäs
country: Sweden
facility: 502.373.1512 Vännäs Vaardcentral
city: Basel
country: Switzerland
facility: 502.373.1625 Boehringer Ingelheim Investigational Site
city: Bellinzona
country: Switzerland
facility: 502.373.1632 Boehringer Ingelheim Investigational Site
city: Bern
country: Switzerland
facility: 502.373.1634 Boehringer Ingelheim Investigational Site
city: Biel/Bienne
country: Switzerland
facility: 502.373.1627 Boehringer Ingelheim Investigational Site
city: Chur
country: Switzerland
facility: 502.373.1631 Boehringer Ingelheim Investigational Site
city: Kreuzlingen
country: Switzerland
facility: 502.373.1633 Boehringer Ingelheim Investigational Site
city: Lausanne
country: Switzerland
facility: 502.373.1639 Boehringer Ingelheim Investigational Site
city: Lugano
country: Switzerland
facility: 502.373.1629 Boehringer Ingelheim Investigational Site
city: St. Gallen
country: Switzerland
facility: 502.373.1628 Boehringer Ingelheim Investigational Site
city: Zürich
country: Switzerland
facility: 502.373.1637 Boehringer Ingelheim Investigational Site
city: Changhua
country: Taiwan
facility: 502.373.0780 Boehringer Ingelheim Investigational Site
city: Chia-Yi
country: Taiwan
facility: 502.373.0779 Boehringer Ingelheim Investigational Site
city: Hualien
country: Taiwan
facility: 502.373.0783 Boehringer Ingelheim Investigational Site
city: Kaohsiung
country: Taiwan
facility: 502.373.0776 Boehringer Ingelheim Investigational Site
city: Kaohsiung
country: Taiwan
facility: 502.373.0778 Boehringer Ingelheim Investigational Site
city: Tainan
country: Taiwan
facility: 502.373.0775 Boehringer Ingelheim Investigational Site
city: Tainan
country: Taiwan
facility: 502.373.0777 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 502.373.0781 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 502.373.0782 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 502.373.0801 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 502.373.0802 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 502.373.0804 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 502.373.0805 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 502.373.0806 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 502.373.0808 Boehringer Ingelheim Investigational Site
city: Khon Kaen
country: Thailand
facility: 502.373.0803 Boehringer Ingelheim Investigational Site
city: Nonthaburi
country: Thailand
facility: 502.373.0807 Boehringer Ingelheim Investigational Site
city: Adana
country: Turkey
facility: 502.373.1651 Cukurova Universitesi Tip Fakultesi
city: Adana
country: Turkey
facility: 502.373.1652 Cukurova Universitesi Tip Fakultesi
city: Ankara
country: Turkey
facility: 502.373.1653 Ankara Hastanesi Endokrinoloji Bölümü
city: Ankara
country: Turkey
facility: 502.373.1656 Baskent Universitesi Tip Fakultesi
city: Ankara
country: Turkey
facility: 502.373.1659 Ankara Universitesi Tip Fakultesi
city: Istanbul
country: Turkey
facility: 502.373.1654 Göztepe SSK Egitim ve Arastirma Hastanesi
city: Istanbul
country: Turkey
facility: 502.373.1655 Cerrahpasa Universitesi Tip Fakultesi
city: Istanbul
country: Turkey
facility: 502.373.1657 Haseki Hastanesi
city: Izmir
country: Turkey
facility: 502.373.1658 Ege Universitesi Tip Fakultesi
city: Kayseri
country: Turkey
facility: 502.373.1650 Erciyes Universitesi Tip Fakultesi Kardiyoloji Anabilim Dali
city: Dnyepropetrovsk
country: Ukraine
facility: 502.373.1730 Boehringer Ingelheim Investigational Site
city: Dnyepropetrovsk
country: Ukraine
facility: 502.373.1731 Boehringer Ingelheim Investigational Site
city: Kharkov
country: Ukraine
facility: 502.373.1728 Boehringer Ingelheim Investigational Site
city: Kharkov
country: Ukraine
facility: 502.373.1732 Boehringer Ingelheim Investigational Site
city: Kharkov
country: Ukraine
facility: 502.373.1733 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 502.373.1725 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 502.373.1726 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 502.373.1727 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 502.373.1729 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 502.373.1734 Boehringer Ingelheim Investigational Site
city: Abu Dhabi
country: United Arab Emirates
facility: 502.373.1680 Boehringer Ingelheim Investigational Site
city: Dubai
country: United Arab Emirates
facility: 502.373.1675 Boehringer Ingelheim Investigational Site
city: Dubai
country: United Arab Emirates
facility: 502.373.1679 Boehringer Ingelheim Investigational Site
city: Sharjah
country: United Arab Emirates
facility: 502.373.1677 Boehringer Ingelheim Investigational Site
city: Aberdeen
country: United Kingdom
facility: 502.373.1698 Boehringer Ingelheim Investigational Site
city: Bathampton
country: United Kingdom
facility: 502.373.1706 Boehringer Ingelheim Investigational Site
city: Belfast
country: United Kingdom
facility: 502.373.1690 Boehringer Ingelheim Investigational Site
city: Birmingham
country: United Kingdom
facility: 502.373.1694 Boehringer Ingelheim Investigational Site
city: Brighton
country: United Kingdom
facility: 502.373.1707 Boehringer Ingelheim Investigational Site
city: Cardiff
country: United Kingdom
facility: 502.373.1703 Boehringer Ingelheim Investigational Site
city: Chichester
country: United Kingdom
facility: 502.373.1709 Boehringer Ingelheim Investigational Site
city: Derby
country: United Kingdom
facility: 502.373.1701 Boehringer Ingelheim Investigational Site
city: Gateshead
country: United Kingdom
facility: 502.373.1705 Boehringer Ingelheim Investigational Site
city: Glasgow
country: United Kingdom
facility: 502.373.1710 Boehringer Ingelheim Investigational Site
city: Kirkcaldy, Fife
country: United Kingdom
facility: 502.373.1700 Boehringer Ingelheim Investigational Site
city: Leeds
country: United Kingdom
facility: 502.373.1691 Boehringer Ingelheim Investigational Site
city: Leicester
country: United Kingdom
facility: 502.373.1699 Boehringer Ingelheim Investigational Site
city: Lincoln
country: United Kingdom
facility: 502.373.1702 Boehringer Ingelheim Investigational Site
city: Liverpool
country: United Kingdom
facility: 502.373.1697 Boehringer Ingelheim Investigational Site
city: London
country: United Kingdom
facility: 502.373.1695 Boehringer Ingelheim Investigational Site
city: Manchester
country: United Kingdom
facility: 502.373.1693 Boehringer Ingelheim Investigational Site
city: Portadown, County Atrim
country: United Kingdom
facility: 502.373.1708 Boehringer Ingelheim Investigational Site
city: Rugby
country: United Kingdom
facility: 502.373.1692 Boehringer Ingelheim Investigational Site
city: Sheffield
country: United Kingdom
facility: 502.373.1696 Boehringer Ingelheim Investigational Site
city: Stirling
country: United Kingdom
facility: 502.373.1704 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References:
citation: Bohm M, Schumacher H, Werner C, Teo KK, Lonn EM, Mahfoud F, Speer T, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Laufs U, Williams B, Yusuf S, Mann JFE. Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. Cardiovasc Diabetol. 2022 Jan 20;21(1):12. doi: 10.1186/s12933-021-01429-w.
citation: Bohm M, Schumacher H, Teo KK, Lonn EM, Lauder L, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S, Mann JFE, Mahfoud F. Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. J Hypertens. 2021 Aug 1;39(8):1602-1610. doi: 10.1097/HJH.0000000000002822.
citation: Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Emrich I, Mancia G, Redon J, Schmieder RE, Sliwa K, Lehrke M, Marx N, Weber MA, Williams B, Yusuf S, Mann JFE. Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. J Hypertens. 2021 Apr 1;39(4):766-774. doi: 10.1097/HJH.0000000000002697.
citation: Mancia G, Schumacher H, Bohm M, Mann JFE, Redon J, Facchetti R, Schmieder RE, Lonn EM, Teo KK, Yusuf S. Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. J Hypertens. 2020 Oct;38(10):2050-2058. doi: 10.1097/HJH.0000000000002567.
citation: Dehghan M, Mente A, Rangarajan S, Mohan V, Lear S, Swaminathan S, Wielgosz A, Seron P, Avezum A, Lopez-Jaramillo P, Turbide G, Chifamba J, AlHabib KF, Mohammadifard N, Szuba A, Khatib R, Altuntas Y, Liu X, Iqbal R, Rosengren A, Yusuf R, Smuts M, Yusufali A, Li N, Diaz R, Yusoff K, Kaur M, Soman B, Ismail N, Gupta R, Dans A, Sheridan P, Teo K, Anand SS, Yusuf S. Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. Am J Clin Nutr. 2020 Apr 1;111(4):795-803. doi: 10.1093/ajcn/nqz348.
citation: Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Marx N, Sliwa K, Weber MA, Williams B, Yusuf S. Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. Eur Heart J. 2019 Jul 1;40(25):2032-2043. doi: 10.1093/eurheartj/ehz149.
citation: Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Ukena C, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S. Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. Eur Heart J. 2020 Jan 7;41(2):231-238. doi: 10.1093/eurheartj/ehy808.
citation: Bohm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Weber MA, Williams B, Yusuf S. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017 Jun 3;389(10085):2226-2237. doi: 10.1016/S0140-6736(17)30754-7. Epub 2017 Apr 5.
citation: Dunkler D, Kohl M, Teo KK, Heinze G, Dehghan M, Clase CM, Gao P, Yusuf S, Mann JF, Oberbauer R. Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union. Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv76-85. doi: 10.1093/ndt/gfv086.
citation: Bohm M, Schumacher H, Leong D, Mancia G, Unger T, Schmieder R, Custodis F, Diener HC, Laufs U, Lonn E, Sliwa K, Teo K, Fagard R, Redon J, Sleight P, Anderson C, O'Donnell M, Yusuf S. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Hypertension. 2015 Mar;65(3):651-61. doi: 10.1161/HYPERTENSIONAHA.114.04568. Epub 2015 Jan 12.
citation: Verdecchia P, Reboldi G, Angeli F, Trimarco B, Mancia G, Pogue J, Gao P, Sleight P, Teo K, Yusuf S. Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease. Hypertension. 2015 Jan;65(1):108-14. doi: 10.1161/HYPERTENSIONAHA.114.04310. Epub 2014 Oct 20.
citation: Lonn EM, Rambihar S, Gao P, Custodis FF, Sliwa K, Teo KK, Yusuf S, Bohm M. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol. 2014 Feb;103(2):149-59. doi: 10.1007/s00392-013-0644-4. Epub 2013 Dec 20.
citation: Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. Eur J Prev Cardiol. 2014 Mar;21(3):299-309. doi: 10.1177/2047487313510678. Epub 2013 Nov 4.
citation: Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators. Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. JAMA Intern Med. 2013 Oct 14;173(18):1682-92. doi: 10.1001/jamainternmed.2013.9051.
citation: Bohm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T, Teo K, Yusuf S. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J. 2013 Aug;166(2):306-314.e7. doi: 10.1016/j.ahj.2013.04.016. Epub 2013 Jun 24.
citation: Dehghan M, Mente A, Teo KK, Gao P, Sleight P, Dagenais G, Avezum A, Probstfield JL, Dans T, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET)/Telmisartan Randomized Assessment Study in ACEI Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Trial Investigators. Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries. Circulation. 2012 Dec 4;126(23):2705-12. doi: 10.1161/CIRCULATIONAHA.112.103234.
citation: Barzilay JI, Gao P, Clase CM, Mente A, Mann JF, Sleight P, Yusuf S, Teo KK; OnTARGET/TRANSCEND Investigators. Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures. Clin J Am Soc Nephrol. 2013 Feb;8(2):233-40. doi: 10.2215/CJN.06640712. Epub 2012 Nov 26.
citation: Kappert K, Bohm M, Schmieder R, Schumacher H, Teo K, Yusuf S, Sleight P, Unger T; ONTARGET/TRANSCEND Investigators. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation. 2012 Aug 21;126(8):934-41. doi: 10.1161/CIRCULATIONAHA.111.086660. Epub 2012 Jul 24.
citation: Neumann I, Grassi B. [Critically appraised article]. Rev Med Chil. 2012 Jan;140(1):117-20. Epub 2012 Apr 12. Spanish.
citation: Verdecchia P, Dagenais G, Healey J, Gao P, Dans AL, Chazova I, Binbrek AS, Iacobellis G, Ferreira R, Holwerda N, Karatzas N, Keltai M, Mancia G, Sleight P, Teo K, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint TrialTelmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies. J Hypertens. 2012 May;30(5):1004-14. doi: 10.1097/HJH.0b013e3283522a51.
citation: Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Bohm M, Williams B, Yusoff K, Teo K, Yusuf S; ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012 Jan 3;59(1):74-83. doi: 10.1016/j.jacc.2011.09.040.
citation: Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, Yusoff K, Ryden L, Liu GL, Teo K, Sleight P, Yusuf S. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011 Oct 18;124(16):1727-36. doi: 10.1161/CIRCULATIONAHA.110.008870. Epub 2011 Sep 26.
citation: Barzilay JI, Gao P, Ryden L, Schumacher H, Probstfield J, Commerford P, Dans A, Ferreira R, Keltai M, Paolasso E, Yusuf S, Teo K; TRANSCEND Investigators. Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study. Diabetes Care. 2011 Sep;34(9):1902-7. doi: 10.2337/dc11-0545. Epub 2011 Jul 25.
citation: Tobe SW, Clase CM, Gao P, McQueen M, Grosshennig A, Wang X, Teo KK, Yusuf S, Mann JF; ONTARGET and TRANSCEND Investigators. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation. 2011 Mar 15;123(10):1098-107. doi: 10.1161/CIRCULATIONAHA.110.964171. Epub 2011 Feb 28.
citation: Barzilay JI, Gao P, O'Donnell M, Mann JF, Anderson C, Fagard R, Probstfield J, Dagenais GR, Teo K, Yusuf S; ONTARGET and TRANSCEND Investigators. Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies. Arch Intern Med. 2011 Jan 24;171(2):142-50. doi: 10.1001/archinternmed.2010.502.
citation: Dans AL, Teo K, Gao P, Chen JH, Jae-Hyung K, Yusoff K, Chaithiraphan S, Zhu J, Lisheng L, Yusuf S; Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial Investigators. In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events. PLoS One. 2010 Dec 21;5(12):e13694. doi: 10.1371/journal.pone.0013694.
citation: Anderson C, Teo K, Gao P, Arima H, Dans A, Unger T, Commerford P, Dyal L, Schumacher H, Pogue J, Paolasso E, Holwerda N, Chazova I, Binbrek A, Young J, Yusuf S; ONTARGET and TRANSCEND Investigators. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011 Jan;10(1):43-53. doi: 10.1016/S1474-4422(10)70250-7. Epub 2010 Oct 25.
citation: Bohm M, Baumhakel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation. 2010 Mar 30;121(12):1439-46. doi: 10.1161/CIRCULATIONAHA.109.864199. Epub 2010 Mar 15.
citation: Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf S; ONTARGET/TRANSCEND Investigators. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation. 2009 Oct 6;120(14):1380-9. doi: 10.1161/CIRCULATIONAHA.109.865774. Epub 2009 Sep 21.
citation: Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Bohm M, Williams B, Pogue J, Koon T, Yusuf S; ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009 Jul;27(7):1360-9. doi: 10.1097/HJH.0b013e32832d7370.
citation: Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Ryden L, Yu CM, Teo KK, Yusuf S; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009 Jul 7;151(1):1-10, W1-2. doi: 10.7326/0003-4819-151-1-200907070-00122. Epub 2009 May 18.
citation: Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators; Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Epub 2008 Aug 29.
citation: Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008 Aug 16;372(9638):547-53. doi: 10.1016/S0140-6736(08)61236-2.
citation: ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31.
citation: Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K; ONTARGET/TRANSCEND Investigators. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation. 2007 Mar 20;115(11):1371-5. doi: 10.1161/CIRCULATIONAHA.106.661405. Epub 2007 Mar 5.